Get the Stockscreener App
32.35
1.33%
-0.44
Amphastar Pharmaceuticals Inc stock is traded at $32.35, with a volume of 130.07K.
It is down -1.33% in the last 24 hours and down -8.21% over the past month.
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
See More
Previous Close:
$32.79
Open:
$32.71
24h Volume:
130.07K
Relative Volume:
0.25
Market Cap:
$1.58B
Revenue:
$723.55M
Net Income/Loss:
$157.72M
P/E Ratio:
10.78
EPS:
3
Net Cash Flow:
$170.15M
1W Performance:
-7.21%
1M Performance:
-8.21%
6M Performance:
-16.80%
1Y Performance:
-38.91%
1-Day Range:
$32.29
$32.95
1-Week Range:
$32.25
$34.39
52-Week Range:
$32.25
$56.45
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Name
Amphastar Pharmaceuticals Inc
Sector
Phone
909-980-9484
Address
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
32.30 | 1.58B | 723.55M | 157.72M | 170.15M | 3.00 |
|
ZTS
Zoetis Inc
|
171.54 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.54 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.545 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.64 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
123.42 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-22-24 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Nov-17-23 | Initiated | BofA Securities | Neutral |
| Jul-25-23 | Resumed | Jefferies | Buy |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jul-29-22 | Initiated | CapitalOne | Overweight |
| Jan-07-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-05-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-01-20 | Initiated | Northland Capital | Outperform |
| Mar-13-19 | Downgrade | Needham | Buy → Hold |
| Mar-13-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-10-18 | Reiterated | Needham | Buy |
| Mar-13-18 | Reiterated | Needham | Buy |
| Dec-01-17 | Reiterated | Needham | Buy |
| Nov-09-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-27-17 | Reiterated | Needham | Buy |
| Mar-14-17 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-09-16 | Reiterated | Needham | Buy |
| May-10-16 | Reiterated | Needham | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| Jun-19-15 | Reiterated | Needham | Buy |
| Jun-03-15 | Initiated | Raymond James | Strong Buy |
| Jul-21-14 | Initiated | Needham | Buy |
View All
Amphastar Pharmaceuticals Inc Stock (AMPH) Latest News
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Holdings Boosted by Boston Trust Walden Corp - MarketBeat
Piper Sandler Downgrades Amphastar Pharmaceuticals (NASDAQ:AMPH) to Neutral - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 52-Week LowHere's Why - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Sees Large Growth in Short Interest - MarketBeat
Piper Sandler Downgrades Amphastar Pharmaceuticals (AMPH) - MSN
Piper Sandler cuts Amphastar stock rating, slashes price target By Investing.com - Investing.com Canada
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap DownHere's What Happened - MarketBeat
Market Resilience: Amphastar Pharmaceuticals Inc (AMPH) Finishes Weak at 33.39, Down -4.24 - The Dwinnex
This Ollie's Bargain Outlet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga India
Piper Sandler Downgrades Amphastar Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $36 From $66 - Marketscreener.com
Long Term Trading Analysis for (AMPH) - Stock Traders Daily
Piper Sandler cuts Amphastar stock rating, slashes price target - MSN
Amphastar stock hits 52-week low at $34.08 amid market challenges - Investing.com India
Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference - ACCESS Newswire
BofA Adjusts Price Target on Amphastar Pharmaceuticals to $44 From $46 -February 03, 2025 at 10:16 am EST - Marketscreener.com
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Purchased by Pacer Advisors Inc. - MarketBeat
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021 - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024 - ACCESS Newswire
(AMPH) Technical Data - Stock Traders Daily
Amphastar Receives FDA Approval for Ganirelix Acetate Injection - ACCESS Newswire
Possible Bearish Signals With Amphastar Pharmaceuticals Insiders Disposing Stock - Simply Wall St
Assenagon Asset Management S.A. Sells 5,956 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Short Interest Up 10.3% in December - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 12-Month LowTime to Sell? - MarketBeat
Amphastar stock hits 52-week low at $34.6 amid market challenges - MSN
Amphastar Pharmaceuticals (NASDAQ:AMPH) Trading Down 2.4%Should You Sell? - MarketBeat
Dextrose Injection Market Size, Share & Trending Opportunities - WICZ
Dextrose Injection Market Size, Share & Trending Opportunities (2024-2031) | Pfizer Inc., Amphastar Pharmaceuticals Inc. - EIN News
Trend Tracker for (AMPH) - Stock Traders Daily
Oversold Conditions For Amphastar Pharmaceuticals (AMPH) - Nasdaq
Amphastar stock hits 52-week low at $34.85 amid market challenges - Investing.com Nigeria
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Up 4.6%What's Next? - MarketBeat
Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - AccessWire
Amphastar stock hits 52-week low at $34.85 amid market challenges By Investing.com - Investing.com South Africa
Amphastar Pharmaceuticals (NASDAQ:AMPH) Sets New 1-Year LowShould You Sell? - MarketBeat
Amphastar Pharmaceuticals: Cheap With Caveats (NASDAQ:AMPH) - Seeking Alpha
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Reasonably Well - Simply Wall St
Short Interest in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Expands By 6.1% - Defense World
Short Interest in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Increases By 6.1% - MarketBeat
Amphastar stock hits 52-week low at $36.55 amid market challenges - Investing.com Australia
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 1-Year LowHere's Why - MarketBeat
Amphastar stock hits 52-week low at $36.55 amid market challenges By Investing.com - Investing.com South Africa
Principal Financial Group Inc. Cuts Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Amphastar Pharmaceuticals Inc Stock (AMPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amphastar Pharmaceuticals Inc Stock (AMPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 12 '24 |
Option Exercise |
11.33 |
7,000 |
79,310 |
125,469 |
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 13 '24 |
Sale |
45.23 |
8,000 |
361,840 |
118,469 |
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 12 '24 |
Sale |
44.42 |
7,000 |
310,975 |
118,469 |
| PRINS RICHARD K | Director |
Dec 09 '24 |
Option Exercise |
19.52 |
10,000 |
195,200 |
40,471 |
| PRINS RICHARD K | Director |
Dec 09 '24 |
Sale |
43.77 |
10,000 |
437,702 |
30,471 |
0.80%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):